The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

October 19, 2021

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

October 18, 2021

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

October 16, 2021

As the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.

October 14, 2021

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.

October 13, 2021

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

October 11, 2021

Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment.

October 11, 2021

Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.

October 11, 2021

Eric Jonasch, MD, discusses recent pivotal developments in treating patients with renal cell carcinoma.

October 07, 2021

Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.

October 04, 2021

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

September 30, 2021

Hussein A. Tawbi, MD, PhD, discusses the safety and efficacy achieved with relatlimab plus nivolumab in the RELATIVITY-047 trial and sheds light on the clinical significance of the data in the melanoma treatment paradigm.

September 30, 2021

Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.

September 28, 2021

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

September 23, 2021

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

September 22, 2021

The phase 1/2 MANIFEST and phase 3 MANIFEST-2 trials are examining a complement to JAK inhibition that could improve responses and disease management up front in patients with myelofibrosis.

September 21, 2021

Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.

September 21, 2021

Kanwal Raghav, MBBS, MD, discusses optimal dosing strategies for regorafenib in patients with colorectal cancer.

September 19, 2021

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.

September 16, 2021

Michael Wang, MD, discusses the significance of p53 mutations in mantle cell lymphoma.

September 16, 2021

Krina K. Patel, MD, MSc, discusses mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.